Home » Business, Health & Medicine, News & Current Affairs, Pharmaceuticals & Biotech » Global Indolent Lymphoma, Metastatic Melanoma And Cancer Cachexia Pipeline Market Review Up To 2015: Radiant Insights
“Radiant Insights”
New Market Research Reports Title “Indolent Lymphoma, Metastatic Melanoma And Cancer Cachexia Pipeline Market Review Up To 2015” Has Been Added to RadiantInsights.com Report Database.

Indolent Lymphoma – Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Scope

• The report provides a snapshot of the global therapeutic landscape of Indolent Lymphoma

• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

• The report reviews key players involved in the therapeutics development for Indolent Lymphoma and enlists all their major and minor projects

• The report summarizes all the dormant and discontinued pipeline projects

• A review of the Indolent Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages


For more Information About Indolent Lymphoma – Pipeline Review, H1 2015 Click:
http://www.radiantinsights.com/research/indolent-lymphoma-pipeline-review-h1-2015

Metastatic Melanoma – Pipeline Review, H1 2015

Global Markets Direct’s, ‘Metastatic Melanoma – Pipeline Review, H1 2015’, provides an overview of the Metastatic Melanoma’s therapeutic pipeline.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Scope

• The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma

• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

• The report reviews key players involved in the therapeutics development for Metastatic Melanoma and enlists all their major and minor projects

• The report summarizes all the dormant and discontinued pipeline projects

• A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources


For more Information About Metastatic Melanoma – Pipeline Review, H1 2015 Click:
http://www.radiantinsights.com/research/metastatic-melanoma-pipeline-review-h1-2015

Cancer Cachexia – Pipeline Review, H1 2015

Global Markets Direct’s, ‘Cancer Cachexia – Pipeline Review, H1 2015’, provides an overview of the Cancer Cachexia’s therapeutic pipeline.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Scope

• The report provides a snapshot of the global therapeutic landscape of Cancer Cachexia

• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

• The report reviews key players involved in the therapeutics development for Cancer Cachexia and enlists all their major and minor projects

• The report summarizes all the dormant and discontinued pipeline projects

• A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources


For more Information About Cancer Cachexia – Pipeline Review, H1 2015 Click:
http://www.radiantinsights.com/research/cancer-cachexia-pipeline-review-h1-2015

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information, visit: http://www.radiantinsights.com/

Blog URL: http://www.terrapass.org/

Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Email: sales@radiantinsights.com
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: Califonia
Country: United States
Website: http://www.radiantinsights.com/research/indolent-lymphoma-pipeline-review-h1-2015

Comments are closed.